



LKT Laboratories, Inc.

Pazopanib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID P0397

CAS No. 444731-52-6

Chemical Name 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide

Synonym GSK-VEG10003; GW786034B; GW-786034

Formula C₂₁H₂₃N₇O₂S

Formula Wt. 437.53

Melting Point 301-313 °C


Purity ≥97%

Solubility

Store Temp Ambient

Ship Temp Ambient

Description Pazopanib is an inhibitor of VEGFR, PDGFR, and c-Kit that displays anticancer chemotherapeutic and anti-angiogenic activities. Pazopanib is clinically used to treat metastatic renal cell carcinoma, but shows potential for a wide variety of other cancers, including ovarian cancer and non-small cell lung cancer (NSCLC). In vitro and in vivo, pazopanib inhibits cell proliferation and angiogenesis, preventing tumor growth. This compound also inhibits wild-type B-Raf, preventing activation of p-ERK1/2 and p-MEK1/2, decreasing brain metastasis volume in animal models of breast cancer.



Bulk quantities available upon request

Product ID	Size
P0397	5 mg
P0397	25 mg
P0397	100 mg

References Pick AM, Nystrom KK. Pazopanib for the treatment of metastatic renal cell carcinoma. Clin Ther. 2012 Mar;34(3):511-20. PMID: 22341567.

Gril B, Palmieri D, Qian Y, et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res. 2011 Jan 1;17(1):142-53. PMID: 21081656.

Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15(6):539-47. PMID: 20511320.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.